{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T07:44:33Z","timestamp":1794987873067,"version":"4.9.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study aimed to investigate the efficacy and safety of baricitinib in patients with severe coronavirus disease 2019 (COVID-19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Databases were searched for studies that compared the clinical efficacy and adverse effects of baricitinib with standard therapy for the treatment of severe COVID-19 and clearly reported relevant outcomes published until December 31, 2022. The corresponding data were extracted from these studies. A fixed-effects model was used to calculate the pooled estimates. The study protocol can be accessed at PROSPERO (CRD42023394173).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The baricitinib group had a significantly lower mortality rate and proportion of patients who received mechanical ventilation than the control group (OR\u2005=\u20050.61, 0.57;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.008, 0.02; 95% CI 0.42\u20130.88; 0.35\u20130.92; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200571% and 86%, respectively). The length of hospital stay and rates of severe adverse events were not significantly different between the 2 groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Baricitinib reduces mortality and mechanical ventilation requirements in patients with severe COVID-19. Therefore, we developed a comprehensive understanding of the role of baricitinib in patients with severe COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000036313","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T22:00:34Z","timestamp":1701468034000},"page":"e36313","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"given":"Wenxin","family":"Song","sequence":"first","affiliation":[{"name":"The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishen","family":"Sun","sequence":"additional","affiliation":[{"name":"Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Feng","sequence":"additional","affiliation":[{"name":"Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liujun","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Gao","sequence":"additional","affiliation":[{"name":"Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxiang","family":"Xian","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5201-0488","authenticated-orcid":false,"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260811","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bj.2020.04.007","article-title":"COVID-19: The first documented coronavirus pandemic in history.","volume":"43","author":"Liu","year":"2020","journal-title":"Biomed J"},{"issue":"Suppl 3","key":"R2-20260811","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12939-022-01767-5","article-title":"The World Health Organization COVID-19 surveillance database.","volume":"21","author":"Allan","year":"2022","journal-title":"I J Equity Health"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08830185.2021.1884248","article-title":"Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality.","volume":"41","author":"Que","year":"2022","journal-title":"Int Rev Immunol"},{"key":"R4-20260811","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19.","volume":"28","author":"van de Veerdonk","year":"2022","journal-title":"Nat Med"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"e1003501","DOI":"10.1371\/journal.pmed.1003501","article-title":"Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis.","volume":"17","author":"Kim","year":"2020","journal-title":"PLoS Med"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling.","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/cid\/ciaa879","article-title":"Use of Baricitinib in patients with moderate to severe coronavirus disease 2019.","volume":"72","author":"Titanji","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R8-20260811","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact.","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"R9-20260811","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/jgs.17357","article-title":"Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia.","volume":"69","author":"Abizanda","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"R10-20260811","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R11-20260811","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin Res ed)"},{"key":"R12-20260811","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/02763869.2019.1588072","article-title":"PROSPERO: an international register of systematic review protocols.","volume":"38","author":"Schiavo","year":"2019","journal-title":"Med Ref Serv Q"},{"key":"R13-20260811","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14 Going from evidence to recommendations: the significance and presentation of recommendations.","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"R14-20260811","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.resinv.2022.02.004","article-title":"Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: a propensity score-matched retrospective cohort study.","volume":"60","author":"Tanimoto","year":"2022","journal-title":"Respir Investig"},{"key":"R15-20260811","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","article-title":"Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.","volume":"60","author":"Rodriguez-Garcia","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"R16-20260811","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jmii.2021.05.009","article-title":"Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: a retrospective analysis.","volume":"54","author":"P\u00e9rez-Alba","year":"2021","journal-title":"J microbiol immunol Infect = Wei mian yu gan ran za zhi"},{"key":"R17-20260811","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12879-021-06119-2","article-title":"Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.","volume":"21","author":"Hasan","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R18-20260811","doi-asserted-by":"crossref","first-page":"749657","DOI":"10.3389\/fmed.2021.749657","article-title":"Impact of the addition of baricitinib to standard of care including tocilizumab and corticosteroids on mortality and safety in severe COVID-19.","volume":"8","author":"Masi\u00e1","year":"2021","journal-title":"Front Med"},{"key":"R19-20260811","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical research ed)"},{"key":"R20-20260811","doi-asserted-by":"crossref","first-page":"1004308","DOI":"10.3389\/fphar.2022.1004308","article-title":"Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: a comparison using systematic review and meta-analysis.","volume":"13","author":"Cherian","year":"2022","journal-title":"Front Pharmacol"},{"key":"R21-20260811","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R22-20260811","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival.","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"R23-20260811","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R24-20260811","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cegh.2020.07.006","article-title":"Antivirals for COVID-19: a critical review.","volume":"9","author":"Frediansyah","year":"2021","journal-title":"Clin Epidemiol Global Health"},{"key":"R25-20260811","doi-asserted-by":"crossref","first-page":"106749","DOI":"10.1016\/j.intimp.2020.106749","article-title":"Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.","volume":"86","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"R26-20260811","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2021.12.010","article-title":"Achieving end-to-end success in the clinic: pfizer\u2019s learnings on R&D productivity.","volume":"27","author":"Fernando","year":"2022","journal-title":"Drug Discov Today"},{"key":"R27-20260811","article-title":"Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients.","author":"Najjar-Debbiny","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R28-20260811","first-page":"e20620","article-title":"Use of baricitinib in combination with remdesivir and steroid in COVID-19 treatment: a multicenter retrospective study.","volume":"13","author":"So","year":"2021","journal-title":"Cureus"},{"key":"R29-20260811","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.","volume":"400","year":"2022","journal-title":"Lancet (London, England)"},{"key":"R30-20260811","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14787210.2021.1982695","article-title":"Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.","volume":"20","author":"Limen","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R31-20260811","doi-asserted-by":"crossref","first-page":"101493","DOI":"10.1016\/j.eclinm.2022.101493","article-title":"Baricitinib as the treatment of choice for hospitalised individuals with COVID-19.","volume":"49","author":"Richardson","year":"2022","journal-title":"EClinicalMedicine"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000036313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:01:47Z","timestamp":1786435307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000036313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":31,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036313","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}